CRC cells carrying KRAS mutations had higher mitochondrial activity than BRAF mutations and showed higher glycolytic activity [13]; thus, KRAS and BRAF should be considered prognostic markers of OXPHOS or glycolysis in CRC patients. This evidence concerns the gene KRAS and colorectal carcinoma.